DILIsym Services Inc.
Research Triangle Park, North Carolina
Brett Howell is the President of DILIsym Services, Inc., a Simulations Plus company developing and using DILIsym software to improve the development of safer drug therapies. He is also an associate director of the DILI-sim Initiative since its inception in 2011. In addition to overseeing DILIsym Services operations, Dr. Howell also helps guide the architecture and use of the DILIsym modeling software. Dr. Howell has published over 30 scientific papers in the areas of PBPK/PD modeling, in vitro toxicity testing, novel drug delivery systems, and drug safety. He has given invited scientific presentations at numerous national and international meetings, including the Society of Toxicology annual meeting, the Japanese Society of Toxicology annual meeting, the annual FDA/AASLD Drug-Induced Liver Injury meeting, the American Conference on Pharmacometrics (ACOP) annual meeting, the European Microsomes and Drug Oxidations annual meeting, and the Drug Information Association (DIA) annual safety meeting. He serves on the editorial board for the prominent Quantitative Systems Pharmacology (QSP) journal, “CPT: Pharmacometrics & Systems Pharmacology,” published by the American Society for Clinical Pharmacology and Therapeutics. Prior to joining DILIsym Services, Dr. Howell was a research investigator and research scientist at The Hamner Institutes for Health Sciences. He holds a Ph.D. in chemical engineering from the University of Florida and Bachelor of Science degrees in chemical engineering and textile engineering from North Carolina State University.